Rezolute's rare disease drug fails to meet main goal in late

Dec 11 (Reuters) – Rezolute said on Thursday its therapy aimed at controlling excessive insulin activity in patients with a rare genetic disorder did not show ‍significant benefit in a late-stage trial.

Shares of the Redwood City-based company fell 90% to $1.06 in premarket trading.

The therapy, called ersodetug, was tested in patients with congenital hyperinsulinism, a condition where the body produces too much insulin and causes severe episodes of ‌low blood sugar. The disease primarily affects ‌children and can lead to brain damage if not properly managed.

The trial, which enrolled 63 patients, failed to meet its main goal of a reduction in weekly low-blood-sugar events.

Patients on the highest dose saw a 45% reduction in the weekly episodes of low blood sugar, but that was ‍not sta